How to Evaluate a Pharma Franchise Partner

Why Partner Evaluation Matters

In the Indian pharma distribution space, hundreds of companies actively seek PCD partners. Not all operate with equal standards of quality, supply reliability, or commercial transparency. A franchise distributor's business reputation is directly tied to the products they place in the market and the company whose brands they promote.

Inadequate due diligence at the partnership selection stage is one of the most frequently cited causes of failure for new distribution ventures. Evaluating a potential partner systematically, before committing capital or professional relationships, is essential.

1. Quality Standards and Manufacturing Compliance

Quality is non-negotiable in healthcare. The foundation of any reputable pharmaceutical company is adherence to verified manufacturing standards. When reviewing potential partners, examine whether manufacturing facilities follow Schedule M of the Drugs and Cosmetics Rules, 1945, and where applicable, World Health Organization Good Manufacturing Practice (WHO-GMP) guidelines.

WHO-GMP certification is issued to manufacturing units that demonstrate consistent adherence to internationally benchmarked production and quality management standards. It is distinct from Schedule M compliance and represents an additional quality layer relevant when products are intended for institutional, export, or higher-tier market segments.

Distributors should verify that products carry genuine batch numbers, manufacturing dates, expiry dates, and tamper-evident packaging. Requesting a Certificate of Analysis (COA) for representative batches helps establish quality consistency and confirms that finished product specifications align with label claims.

2. Product Portfolio Breadth and Dosage Form Diversity

A competitive partner must offer a balanced portfolio across key therapeutic segments. This ensures you can cater to a broad prescriber base — from general physicians managing acute infections and gastrointestinal complaints to specialists in orthopedics, obstetrics, pediatrics, and dermatology.

Equally vital is dosage form variety. Medical practitioners prescribe distinct formulations depending on patient age, condition severity, and compliance considerations: tablets, capsules, oral suspensions, drops, injectables, ointments, sachets, and respiratory solutions (respules). A partner offering broad dosage coverage reduces the need to manage multiple supplier accounts.

3. Packaging Durability and Labeling Clarity

Pharmaceutical packaging serves a dual purpose: protecting active ingredient stability against humidity, temperature fluctuation, light, and physical damage during transit, while presenting clear, compliant statutory labeling.

4. Supply Chain Consistency and Order Turnaround

Frequent stock-outs are among the most common reasons distributors switch pharma partners. When a prescription is generated and the product is unavailable at the chemist, both the practitioner's recommendation and the distributor's credibility are affected.

Inquire about typical turnaround times from purchase order placement to dispatch. Ask about the company's approach to fast-moving molecules — whether they maintain safety stock or operate on batch-to-batch availability. Also clarify lead times for newly introduced or slow-moving SKUs.

Established partners maintain robust stock reserves for high-demand formulations and provide transparent visibility into production and dispatch schedules.

5. Transparent Commercial and Operational Terms

Ethical pharmaceutical companies maintain written clarity regarding billing terms, dispatch mechanisms, minimum order quantities, and territory understandings. Ambiguity on any of these points is a risk factor.

Specifically request: the list of products available in your territory and whether they are exclusive or open, the billing cycle and credit terms if any, the return and damage policy, and the process for price revisions.

Avoid companies that make speculative promises of guaranteed earnings or unrealistic monthly turnover projections. Distribution income depends on territory size, prescriber density, your field effort, and competition — no company can legitimately guarantee specific financial outcomes.

6. Promotional Support and Field Materials

Field promotion is resource-intensive. Professional pharma companies support their distribution partners with visual aids (detailing folders, product cards), samples where permitted, catch covers, prescription pads, and product information literature.

Assess what promotional inputs are offered and whether they are included in the franchise arrangement or separately billed. The quality and accuracy of these materials reflect the company's investment in professional standards.

7. Regulatory Standing and Complaint History

Publicly available information from State Drug Control and Central Drugs Standard Control Organisation (CDSCO) sources, including recall notices and show-cause orders, can indicate a company's regulatory track record. Frequent regulatory actions or recall history warrants careful scrutiny.

While not all distributors will conduct formal regulatory database checks, asking directly about any recalled batches in the past two to three years and reviewing the company's response is a reasonable due diligence step.